Updates

We have advised a large MedTech company on the structuring of its collaboration with Dutch healthcare providers and healthcare professionals for clinical research and product development purposes.

We have advised a digital health start-up on the qualification of its services under Dutch healthcare law, including the determination of whether the company qualifies as a healthcare provider and the resulting regulatory obligations.

We have advised a healthcare provider on compliance with the Dutch Healthcare Quality, Complaints and Disputes Act (Wkkgz), including the implementation of an internal complaints procedure and the appointment of a complaints officer.

We have assisted a medical device manufacturer in assessing whether its product is eligible for reimbursement under Dutch healthcare insurance law.

We have assisted a healthcare start-up with the regulatory requirements for establishing a healthcare institution in the Netherlands, including the required permits and governance structure.

Axon assisted the shareholders of a Dutch medtech company, specialising in epilepsy detection devices, in the sale of the company to a Scandinavian healthcare technology group. We advised on the transaction structure, share purchase documentation and related matters.

Axon assisted a Dutch IVD company in securing a EUR 24M equity financing round, advising on the transaction structure, investment documentation and related matters.

Axon advised a stock-listed biopharmaceutical company on antibody licensing and technology transfer agreements with two major US-based pharmaceutical companies. The deals involved the grant of commercial rights to the licensor's proprietary antibody platform technology.

Axon assisted a Dutch oncology company, developing small molecule inhibitors for the precision treatment of cancer, with the structuring and completion of its Series A financing round. We advised on the drafting of all corporate resolutions, conditions precedent and related filtering and closing matters.

We have advised pharmacies on the regulatory aspects of pharmaceutical compounding.